Current Opinion in Neurology

Papers
(The H4-Index of Current Opinion in Neurology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Medical technologies, telemedicine and artificial intelligence for neurotrauma and neurorehabilitation71
Management of neuropsychiatric symptoms in dementia56
Cortical hyperexcitability in amyotrophic lateral sclerosis: from pathogenesis to diagnosis53
The recent surge of functional movement disorders: social distress or greater awareness?42
Chemotherapy and targeted therapies for meningiomas: what is the evidence?42
Update on management of cerebral venous thrombosis40
Historical development and contemporary use of neuromodulation in human spinal cord injury40
The role of the gut microbiome in Alzheimer's disease pathophysiology40
Hereditary motor neuropathies38
From basic mechanisms to therapeutic perspectives in cluster headache37
Editorial introductions31
Central nervous system adverse events of immune checkpoint inhibitors29
Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies28
Neurology education in the era of artificial intelligence28
The 2021 WHO classification of central nervous system tumors: what neurologists need to know27
Microglia in multiple sclerosis – pathogenesis and imaging24
Gene therapies for CMT neuropathies: from the bench to the clinic24
Editorial: Epilepsy advances in 202324
T cell dysfunction in glioblastoma: a barrier and an opportunity for the development of successful immunotherapies24
Equitable partnerships between scientists and persons living with spinal cord injury will strengthen research scope, quality, and outcomes23
Editorial introductions22
Development of neural repair therapy for chronic spinal cord trauma: soluble nogo receptor decoy from discovery to clinical trial21
New chronic inflammatory demyelinating polyneuropathy/Guillain–Barré syndrome guidelines – impact on clinical practise21
0.072058916091919